MXPA06013585A - Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas. - Google Patents
Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas.Info
- Publication number
- MXPA06013585A MXPA06013585A MXPA06013585A MXPA06013585A MXPA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A MX PA06013585 A MXPA06013585 A MX PA06013585A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pharmaceutical formulations
- making
- acid secretion
- formulations useful
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009858 acid secretion Effects 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 4
- 208000010643 digestive system disease Diseases 0.000 abstract 4
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 4
- 239000000126 substance Substances 0.000 abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 230000001458 anti-acid effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57466304P | 2004-05-25 | 2004-05-25 | |
| US57464604P | 2004-05-25 | 2004-05-25 | |
| PCT/US2005/018585 WO2005115474A1 (en) | 2004-05-25 | 2005-05-25 | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06013585A true MXPA06013585A (es) | 2009-07-22 |
Family
ID=35450661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06013585A MXPA06013585A (es) | 2004-05-25 | 2005-05-25 | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1750767A4 (enExample) |
| JP (1) | JP2008500365A (enExample) |
| CA (1) | CA2566655C (enExample) |
| MX (1) | MXPA06013585A (enExample) |
| WO (1) | WO2005115474A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008067037A2 (en) * | 2006-10-05 | 2008-06-05 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| SG190717A1 (en) * | 2010-12-03 | 2013-07-31 | Takeda Pharmaceutical | Orally disintegrating tablet |
| JP6641626B2 (ja) * | 2015-12-25 | 2020-02-05 | エスエス製薬株式会社 | 制酸用医薬組成物 |
| BR112020000084A2 (pt) * | 2017-07-07 | 2020-07-07 | Dsm Ip Assets B.V. | comprimidos compactados |
| KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
| KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
| CN112839635A (zh) * | 2018-08-23 | 2021-05-25 | 株式会社钟根堂 | 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂 |
| CN114555082B (zh) * | 2019-07-26 | 2024-08-16 | 株式会社钟根堂 | 包含埃索美拉唑及碳酸氢钠的稳定的药剂学组合物 |
| KR102573842B1 (ko) * | 2020-02-21 | 2023-09-01 | 주식회사 종근당 | 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| IL159129A0 (en) * | 2001-06-01 | 2004-05-12 | Pozen Inc | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs |
| CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
| AU2005213472A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| AU2005249367A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
-
2005
- 2005-05-25 MX MXPA06013585A patent/MXPA06013585A/es active IP Right Grant
- 2005-05-25 CA CA2566655A patent/CA2566655C/en not_active Expired - Fee Related
- 2005-05-25 JP JP2007515351A patent/JP2008500365A/ja active Pending
- 2005-05-25 EP EP05755940A patent/EP1750767A4/en not_active Withdrawn
- 2005-05-25 WO PCT/US2005/018585 patent/WO2005115474A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2566655C (en) | 2013-04-16 |
| CA2566655A1 (en) | 2005-12-08 |
| EP1750767A1 (en) | 2007-02-14 |
| JP2008500365A (ja) | 2008-01-10 |
| WO2005115474B1 (en) | 2006-02-23 |
| WO2005115474A1 (en) | 2005-12-08 |
| EP1750767A4 (en) | 2010-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006127044A3 (en) | Pharmaceutical formulations useful for inhibiting acid secretion | |
| WO2008067037A3 (en) | Novel formulations of proton pump inhibitors and methods of using these formulations | |
| TW200509923A (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
| MY162319A (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| MXPA06013585A (es) | Formulaciones farmaceuticas utiles para inhibir la secrecion de acido y metodos para hacer y utilizar las mismas. | |
| BRPI0910182A2 (pt) | composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto" | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| MX2009006056A (es) | Formulacion de matriz sensible al ph. | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| WO2010148007A3 (en) | Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| IS6557A (is) | Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun | |
| TNSN07417A1 (en) | Pharmaceutical compositions comprising imatinib and a release retardant | |
| TW200608975A (en) | Pharmaceutical compositions | |
| JO2564B1 (en) | A method for treating atherosclerosis, lipodystrophy and related conditions and pharmaceutical compositions | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| MXPA01012882A (es) | Composiciones y metodos que comprenden gluconato de morfina. | |
| MX383752B (es) | Forma de dosificación oral de liberación sostenida gastro retentiva de un secuestrante de ácido biliar. | |
| AR045061A1 (es) | Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido | |
| BRPI0518205A (pt) | uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino | |
| ATE526988T1 (de) | Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren | |
| EA200601286A1 (ru) | Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |